Nothing Special   »   [go: up one dir, main page]

TR200102493T2 - Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE. - Google Patents

Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE.

Info

Publication number
TR200102493T2
TR200102493T2 TR2001/02493T TR200102493T TR200102493T2 TR 200102493 T2 TR200102493 T2 TR 200102493T2 TR 2001/02493 T TR2001/02493 T TR 2001/02493T TR 200102493 T TR200102493 T TR 200102493T TR 200102493 T2 TR200102493 T2 TR 200102493T2
Authority
TR
Turkey
Prior art keywords
epsilon
ige
epitopes
domains
immunoprophylaxis
Prior art date
Application number
TR2001/02493T
Other languages
Turkish (tr)
Inventor
Friede Martin
Mason Sean
Gordon Turnell William
Paulette Van Mechelen Marcelle
Vinals Y De Bassols Carlota
Original Assignee
Smithkline Beecham Biologicals S.A.
Acambis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Smithkline Beecham Biologicals S.A., Acambis Research Limited filed Critical Smithkline Beecham Biologicals S.A.
Publication of TR200102493T2 publication Critical patent/TR200102493T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Bu bulus alerjik hastaliklarin tedavisi, önlenmesi veya hafifletilmesine iliskin yeni ilaçlarin temini ile ilgilidir. Özellikle, bu yeni ilaçlar, IgE'nin C-espilon-3 veya C-epsilon-4 alanlarindan türetilen epitoplar veya mimotoplardir. Bu yeni bölgeler gerek pasif gerekse aktif immünoprofilaksi veya immünoterapi için hedef olusturabilirler. Bu bulus ayrica ilaçlarin, bunlari içeren farmasötik bilesimlerin üretimi ve bunlarin tipta kullanimina iliskin yöntemlerle de ilgilidir. Ayrica, bu bulus kapsamindaki IgE bölgelerine baglanma kabiliyetine sahip ligandlar, özellikle monoklonal antikorlar ve bunlarin pasif immünoterapi veya immünoprofilaksi olarak kullanilmasi bu bulusun bir baska yönünü olusturmaktadir.This invention relates to the provision of new drugs for the treatment, prevention or alleviation of allergic diseases. In particular, these new drugs are epitopes or mimotopes derived from the C-espilon-3 or C-epsilon-4 domains of IgE. These new sites can be targets for both passive and active immunoprophylaxis or immunotherapy. This invention also relates to methods for the production of medicines, pharmaceutical compositions containing them, and their use in type. In addition, ligands capable of binding to the IgE regions of this invention, particularly monoclonal antibodies and their use as passive immunotherapy or immunoprophylaxis are another aspect of this invention.

TR2001/02493T 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE. TR200102493T2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine

Publications (1)

Publication Number Publication Date
TR200102493T2 true TR200102493T2 (en) 2002-02-21

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02493T TR200102493T2 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE.

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (en) * 1999-12-21 2001-06-28 Acambis Research Limited A reversible linkage technology for controlled conjugation
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
JP2003047482A (en) 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
ES2335979T3 (en) 2001-09-14 2010-04-07 Cytos Biotechnology Ag IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
MXPA05000277A (en) 2002-07-17 2005-03-31 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein.
RU2326693C2 (en) 2002-07-18 2008-06-20 Цитос Байотекнолоджи Аг Hapten-carrier conjugates and application
RU2450827C2 (en) 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Vaccine compositions containing beta 1-6 amyloid antigen array
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ZA200507063B (en) 2003-03-26 2007-03-28 Cytos Biotechnology Ag Packaging of immunostimulatory oligonucleotides into virus-like particles: Method of preparation and use
JP2008507474A (en) * 2004-02-02 2008-03-13 タノックス インコーポレイテッド Identification of novel IgE epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
WO2007041171A2 (en) 2005-09-29 2007-04-12 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
US8541559B2 (en) 2006-06-12 2013-09-24 Cytos Biotechnology Ag Process for producing aggregated oligonucleotides
MX2011006077A (en) 2008-12-09 2011-09-01 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE.
CA2800774A1 (en) * 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
EP2862873B1 (en) * 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
EP3779443A4 (en) * 2018-04-06 2022-05-04 Slsbio Co., Ltd. Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
WO2024155914A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Hair care appliance with powered attachment
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
ES2193136T3 (en) * 1991-08-14 2003-11-01 Genentech Inc IMMUNOGLUBINE VARIANTS FOR SPECIFIC RECEIVERS OF FC EPSILON.
US6610297B1 (en) * 1996-03-01 2003-08-26 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
CO5231139A1 (en) 2002-12-27
MXPA01008612A (en) 2003-06-24
AR029619A1 (en) 2003-07-10
JP2002537403A (en) 2002-11-05
AU3281100A (en) 2000-09-14
PL350992A1 (en) 2003-02-24
KR20020007314A (en) 2002-01-26
IL145025A0 (en) 2002-06-30
NO20014131D0 (en) 2001-08-24
HK1043134A1 (en) 2002-09-06
NZ513680A (en) 2001-09-28
NO20014131L (en) 2001-10-02
CN1520423A (en) 2004-08-11
WO2000050461A1 (en) 2000-08-31
HUP0105490A2 (en) 2002-04-29
CZ20013081A3 (en) 2002-02-13
HUP0105490A3 (en) 2002-05-28
EP1155038A1 (en) 2001-11-21
CA2363641A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
TR200102493T2 (en) Epitopes or mimotopes derived from the C-epsilon-3 or C-epsilon-4 domains of IgE.
ATE403680T1 (en) PRODUCTION OF TETRAVALENT ANTIBODIES
BR0011838A (en) Stacked static mixing elements
ATE454124T1 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF
WO1998057994A3 (en) Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
ATE168013T1 (en) HUMANIZED CHIMERA ANTI-''ICAM-1'' ANTIBODIES, PRODUCTION METHOD AND USE
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
PT724456E (en) ANTIBODIES AGAINST CD4
ATE472338T1 (en) ANTI-CD70 ANTIBODY DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
EP1516185A4 (en) PRESENTATION OF MONOCLONAL ANTIBODIES AND TREATMENT OF TUMORS EXPRESSING MET AND BINDING THE HEPATOCYTIC GROWTH FACTOR
ATE419872T1 (en) PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUS ANTIGENS
DE60033649D1 (en) COMPOUNDS AND THERAPEUTIC METHODS
EP0350690A3 (en) Neutralisation of the in vitro and in vivo toxic properties of tnf-alpha by monoclonal antibodies and by fragments derived therefrom
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
TR200102506T2 (en) Epitopes or mimotopes derived from Ige's C-epsilon-2 domain
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
MA29625B1 (en) IMMUNOGLOBULIN
HK1063601A1 (en) Compositions and methods for treating hyperimmune response in the eye
TR200103638T2 (en) IL-8 Receptor antagonists
ATE252374T1 (en) ENCAPSULATED ANTIBODY PRODUCING CELLS
IL187595A (en) Pharmaceutical composition comprising a monoclonal antitumor antibody and its manufacture
EP1434799A4 (en) DNA MOLECULES AND RECOMBINANT DNA MOLECULES FOR THE PREPARATION OF HUMANIZED MONOCLONAL ANTIBODIES TO S.MUTANS
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases